Global Marfan Syndrome Treatment Market - 2021-2028
The global marfan syndrome treatment market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Marfan syndrome is an inherited disorder affecting connective tissue, consisting of fibres that support and anchor organs and other body structures. The heart, eyes, blood vessels, and skeleton are the most commonly affected organs in Marfan syndrome.
There are many factors driving the market growth of marfan syndrome treatment, one such important driver which is expected to drive the market growth is the increasing research and development.
Increasing research and development is expected to drive the global marfan syndrome treatment market in the forecast period
Marfan syndrome is a genetic condition. It is caused by a mutation in the gene that controls how the body produces fibrillin. Fibrillin is a protein that is important in the connective tissue of your body. Marfan syndrome is usually inherited from one's parents. If you have Marfan syndrome, you have a 50% chance of passing the faulty gene on to your children. A spontaneous mutation causes Marfan syndrome in approximately one out of every four cases. As a result, the affected person is the first in their family to be affected by the condition. The Center for Marfan Syndrome and Related Aortic Disorders prioritizes molecular genetic research on Marfan syndrome and other inherited aortic disorders. Pioneering work in cardiovascular surgery has led to increased research and practice in all aspects of cardiac care. Clinicians and researchers at the Falk Center for Cardiovascular Research and the Donald W. Reynolds Cardiovascular Clinical Research Center are pushing the boundaries of knowledge and improving their understanding and ability to diagnose and treat Marfan syndrome and other aortic disorders.
On August 3rd 2021, The marfan foundation updated its research grant program to support transformative science. The Marfan Foundation's Research Grant Program is intended to provide financial assistance to investigators working on any or all aspects of Marfan syndrome, VEDS, EDS, LDS, and other genetic aortic and vascular conditions. Grants are awarded based on proposal evaluation by The Marfan Foundation Scientific Advisory Board, with the Board of Director's approval.
Limited scientific data and treatment availability is expected to hamper the market growth
There is no cure for Marfan syndrome, treatment focuses on preventing the disease's various complications. Following the publication of several scientific research publications showing an increased risk of aortic aneurysm and dissections when using this type of antibiotic in Marfan Syndrome patients and related disorders. On December 20 2018, the FDA issued a warning regarding the use of fluoroquinolones antibiotic in Marfan patients.
The EMA (European Medicine Agency) previously reported other side effects of this particular antibiotic, but the risk of the aortic aneurysm has yet to be added to this list. Several national health organizations have already revised their guidelines.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies, along with governments worldwide, are collaborating to address the COVID-19 outbreak, from vaccine development to planning for medicine supply chain challenges. Approximately 115 vaccine candidates and 155 molecules are currently in the R&D pipeline. Furthermore, commonly used drugs such as hydroxychloroquine have seen a dramatic increase in demand for COVID-19 management. Because of the high demand for these drugs, manufacturers of COVID-19 management drugs have a lot of opportunities, as many developed countries are running out of them. As a result, the pharmaceutical and biotechnology industries are expected to grow significantly. This in turn is expected to drive the global marfan syndrome treatment market.
Aortic dilation segment is expected to dominate the global marfan syndrome treatment market
The aorta can be weakened by Marfan syndrome. The heart pumps more blood than usual during pregnancy. This can put additional strain on the aorta, increasing the risk of a fatal dissection or rupture. The goal of Marfan syndrome surgery is to prevent aortic dissection or rupture and to treat valve problems. Surgery is recommended if the aorta diameter is greater than 4.7 cm (centimeters) to 5.0 cm (depending on the patient's height) or if the aorta is enlarging rapidly. A cardiologist may also compute the aortic root diameter to height ratio, as this may influence whether or not you should have surgery. During surgery, the dilated aorta is replaced with a graft. Valve repair or replacement surgery is required if Marfan syndrome causes a leaky aortic or mitral valve (regurgitation), changes in the left ventricle (left lower chamber of the heart), or heart failure.
In MFS, surgical treatment of the dilated or dissected aortic root has also evolved over the last 30 years. The composite graft, which consisted of a prosthetic valve fixed in a vascular conduit to which the coronary arteries were anastomosed, was the first significant advancement. The continued excellent results in many reports around the world have resulted in a progressive reduction in the aortic root diameter at which prophylactic repair is advised.
North America region accounted for the largest market share in the global marfan syndrome treatment market
The increasing incidence of marfan syndrome in North America region and the improving healtcare is expected the drive the market in this region.
Marfan syndrome affects approximately 50,000 people in the United States (or three out of every 5,000 people). Marfan syndrome affects both men and women. It occurs in one out of every 20,000 live births.
On November 29,2020, Unichem Laboratories received ANDA approval from the United States Food and Drug Administration (USFDA) for its Atenolol and Chlorthalidone Tablets, 50 mg/25 mg and 100 mg/25 mg to market a generic version of Alvogen Malta Operations' TENORETIC (atenolol and chlorthalidone) Tablets. They are prescribed to treat hypertension and lower blood pressure which is one of the side effects of marfan syndrome.
The global marfan syndrome treatment market is moderately competitive with limited drug approvals, company acquisitions and mergers.
Some of the major keyplayers in this market are Zydus Cadila Healthcare Ltd., Aurobindo Pharma USA, Teva Pharmaceuticals, Merck, Lupin Pharmaceuticals, Inc., AdvaCare Pharma, Tianyu Pharmaceutical Co., Ltd., Trumac Healthcare and Sun Pharmaceutical Industries Ltd. .
Zydus Cadila Healthcare Ltd.
Overview: Cadila Healthcare Limited is a pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company primarily manufactures generic drugs.
Product Portfolio: Zydus Cadila Healthcare Ltd offers a wide variety of zydus generics, including atenolol. This medication is used to treat hypertension. Lowering blood pressure helps to avoid strokes, heart attacks, and kidney problems. Atenolol is a beta-blocker, which is a type of medication.
Key Development:On March 12,2019, The US FDA granted market approval for Atenolol and Chlorthalidone Tablets USP , 50 mg/25 mg and 100 mg/25 mg. It will be produced at the company's manufacturing facility in Ahmedabad's SEZ.
Why Purchase the Report?
• Visualize the composition of the global marfan syndrome treatment market segmentation by treatment and end-user highlighting the key commercial assets and players.
• Identify commercial opportunities in global marfan syndrome treatment market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of global marfan syndrome treatment market- level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players
The global marfan syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
Global Marfan Syndrome Treatment Market- By Treatment
• Aortic Dilation
o Atenolol (Beta Blocker)
o Losartan (Angiotensin receptor blocker)
Global Marfan Syndrome Treatment Market- By End-User
• Speciality Clinics
Global Marfan Syndrome Treatment Market- By Region
• North America
• South America
• Asia Pacific
• Middle East and Africa
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook